Jerash Holdings (US)에 대한 매도 수량은 투자자에게 Jerash Holdings (US)의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Jerash Holdings (US) (NASDAQ:JRSH) 주식, 공매도 수량 보고

Jerash Holdings (US)

Jerash Holdings (US) Inc along with its subsidiaries is a manufacturer and exporter of customized, ready-made sport and outerwear from knitted fabric from its production facilities in Jordan. The company manufactures for retailers namely Walmart, Costco, Sears, Hanes, Columbia, Land's End, VF Corporation, and Philip-Van Heusen which owns brands such as The North Face, Nautica, Timberland, Wrangler, Lee, Jansport, Calvin Klein, Tommy Hilfiger, IZOD, Speedo etc. It derives its revenue from the manufacturing and sales of outerwear in the United States. The company's product offering consists of jackets, polo shirts, crew neck shirts, pants, and shorts made from knitted fabric. Geographically, the company generates maximum revenue from the United States.

Konskie,,Poland,-,January,31,,2024:,Factset,Company,Logo,Displayed

Pre-Market Outlook

AGMH

JRSH

월요일 주목해야 할 주식: 팩트셋 리서치, 커머셜 메탈스, AGM 그룹, 제라시 홀딩스 및 KB홈

Jerash Holdings (US), Inc. - Common Stock

Jerash Holdings (US) Inc

<a href="https://www.chicagofed.org/publications/speeches/2025/june-23-milwaukee-business-journal">https://www.chicagofed.org/publications/speeches/2025/june-23-milwaukee-business-journal</a>

News

Politics

Economics

General

Fed's Goolsbee Says Critical To Look At Soft Economic Data At Current Moment Of Transition

Goldman Sachs analyst Noah Poponak maintains RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) with a Neutral and raises the price target from $114 to $126.

Price Target

Analyst Ratings

Goldman Sachs Maintains Neutral on RTX, Raises Price Target to $126

WIIM

CLBR

CLBR stock has given up its prior gain. Colombier Acquisition Corp. II shares were trading higher after the SEC declared the registration statement on Form S-4 in connection with its proposed business combination with GrabAGun effective.

Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) on Monday announced positive topline results from the Phase 3 HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH) functional class (FC) II or III at intermediate or high <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">risk of disease progression</a>.
HYPERION met its primary endpoint of time to clinical worsening (TTCW) as measured by a composite endpoint of all-cause death, the need for non-planned PAH-related hospitalization &gt; 24 hours, atrial septostomy, lung transplantation, or PAH deterioration.
In HYPERION, Winrevair added on top of background therapy (72.2% of patients on double therapy) within 12 months after initial diagnosis of PAH demonstrated a statistically significant and clinically meaningful reduction in the risk of clinical worsening events <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46048204/merck-announces-phase-3-hyperion-study-of-winrevair-sotatercept-csrk-met-primary-endpoint-in-recen" rel="noreferrer noopener">compared to placebo</a>.
Also Read: <a href="https://www.benzinga.com/25/01/42768614/uk-approves-mercks-hypertension-drug-acquired-via-11-billion-acceleron-pharma-deal" target="_blank" rel="noreferrer noopener">UK Approves Merck&#8217;s Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal</a>
HYPERION is the third Phase 3 study of Winrevair to demonstrate significant efficacy in adults with PAH.
The first was the STELLAR study previously <a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fnews%2Fmercks-investigational-activin-signaling-inhibitor-sotatercept-improved-six-minute-walk-distance-by-40-8-meters-at-week-24-versus-placebo-in-adults-with-pulmonary-arterial-hypertension-on-bac%2F&amp;esheet=54280587&amp;newsitemid=20250623646523&amp;lan=en-US&amp;anchor=presented&amp;index=1&amp;md5=6cc60765e3d6cde225b93aee37881f92" rel="noreferrer noopener">presented</a> at ACC.23, followed by the ZENITH study <a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fnews%2Fwinrevair-sotatercept-csrk-reduced-the-risk-of-a-composite-of-all-cause-death-lung-transplantation-and-hospitalization-for-pulmonary-arterial-hypertension-pah-by-76-compared-to-placebo-i%2F&amp;esheet=54280587&amp;newsitemid=20250623646523&amp;lan=en-US&amp;anchor=presented&amp;index=2&amp;md5=416e4c2984a4485bc2a8d46a139c5585" rel="noreferrer noopener">presented</a> at ACC.25.
In contrast to HYPERION, these previous studies included a patient population in which the majority of participants were on triple therapy. The safety profile of Winrevair was generally consistent with that observed in previous studies.
As <a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fnews%2Fmerck-announces-decision-to-stop-phase-3-hyperion-trial-evaluating-winrevair-sotatercept-csrk-early-and-move-to-final-analysis%2F&amp;esheet=54280587&amp;newsitemid=20250623646523&amp;lan=en-US&amp;anchor=announced&amp;index=3&amp;md5=4445fa17ab52f0b3036f80bce258ea20" rel="noreferrer noopener">announced</a> in January, HYPERION was stopped early and moved to final analysis based on the positive results from the interim analysis of the Phase 3 ZENITH trial and a review of the totality of data from the WINREVAIR clinical program to date.
All patients were offered the opportunity to receive Winrevair through the SOTERIA open-label extension study.
Winrevair is currently approved in more than 45 countries based on the results <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37958211/mercks-11b-bet-pays-as-fda-approves-sotatercept-for-rare-lung-disease" rel="noreferrer noopener">from the STELLAR study</a>.
Price Action: MRK stock is trading higher by 0.44% to $79.41 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46035838/european-advisory-panel-backs-conditional-approval-for-madrigals-fatty-liver-disease-drug" target="_blank" rel="noreferrer noopener">European Advisory Panel Backs Conditional Approval For Madrigal&#8217;s Fatty Liver Disease Drug</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

Large Cap

Health Care

Merck's Hypertension Drug Cuts Clinical Worsening Risk In Over 70% Of Patients On Double Background Therapy

<a href="https://www.bloomberg.com/news/articles/2025-06-23/northern-trust-commits-to-staying-independent-after-bny-report?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2025-06-23/northern-trust-commits-to-staying-independent-after-bny-report?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-06-23/northern-trust-commits-to-staying-independent-after-bny-report?srnd=homepage-americas</a>

NTRS

'Northern Trust Commits To Staying Independent After BNY Report' - Bloomberg

Goldman Sachs analyst Noah Poponak maintains Ducommun (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCO#NYSE">DCO</a>) with a Buy and raises the price target from $84 to $94.

Goldman Sachs Maintains Buy on Ducommun, Raises Price Target to $94

Howard Hughes Holdings shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral and lowered its price target from $82 to $76.

Goldman Sachs analyst Bonnie Herzog maintains Boston Beer Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) with a Sell and lowers the price target from $219 to $187.

Goldman Sachs Maintains Sell on Boston Beer Co, Lowers Price Target to $187

IAMGOLD shares are trading higher after the company announced its  Côté Gold Mine reached a milestone.

RBC Capital analyst Steven Shemesh maintained CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) <a href="https://www.benzinga.com/quote/KMX/analyst-ratings" target="_blank" rel="noreferrer noopener">with an Outperform</a> and raised the price target from $80 to $81 on Friday.
CarMax <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/06/46025302/carmax-makes-the-most-of-booming-used-car-market-stock-soars" rel="noreferrer noopener">reported first-quarter</a> earnings per share of $1.38, beating the&nbsp;analyst consensus estimate of $1.21. Quarterly sales of $7.55 billion outpaced the analyst consensus estimate of $7.47 billion.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46005513/carmax-analyst-backing-despite-rising-delinquencies-healthy-market-sourcing-strength" target="_blank" rel="noreferrer noopener">CarMax Loan Delinquencies Tick Higher In May, Signaling Renewed Credit Strain</a>
Retail used unit sales rose by 9.0%, while comparable store used unit sales grew by 8.1%. Wholesale unit sales also saw a modest increase of 1.2%.
CarMax posted better-than-feared results, with notable upside surprises on used unit comp and gross profit, Shemesh said.
The analyst was encouraged by momentum but remains somewhat cautious about the sustainability of the current comp trend, given macro uncertainty.
He said that retail used unit comp sales grew +8.1%, topping the consensus of +6.3%.
Management shared that each month of the quarter was positive, with April the strongest, Shemesh noted.
The analyst noted that strength was driven by a sequential improvement in category demand (in part due to tariff-related pull forward) and market share gains.
He noted that SG&amp;A as a percentage of gross profit levered ~680 bps to 73.8%, driven by ongoing cost management efforts, partially offset by an increase in compensation and benefits costs (related to unit volume growth).
Shemesh said this is the first quarter since the first quarter of 2024 that CarMax has delivered SG&amp;A as a proportion of gross profit below ~80%.
The analyst noted that CarMax repurchased $200 million of shares in the quarter, a sizable step up from the recent trend.
He said that, for context, CarMax repurchased $429 million and $94 million in 2024 and 2023, respectively.
As of May 31, the company has $1.74 billion left in repurchase authorization, Shemesh noted.
Management indicated that vehicles priced below $20,000 and above $40,000 were the biggest contributors to sales during the quarter, the analyst noted. Specifically, he highlighted that sales of their "Value Max" vehicles — which are older models — rose by 5 percentage points.
Among the stock negatives, CAF income declined 3.6% to $141.7, roughly in line with consensus of $143 million, due to an increase in loan loss provisions, as first-quarter typically requires larger provisions due to seasonally higher sales and lower credit quality period, loss performance, particularly from 2022 and 2023 vintages as well as an uncertain economic outlook and the continued build-out of full spectrum lending capabilities, Shemesh noted.
For 2025 and 2026, Shemesh modeled net sales growth of +1.9% and +3.9% (down from +2.6% and +5.3% prior) and adjusted EPS $3.88 and $4.52 (up from prior $3.66 and $4.31 prior).
Price Action: KMX stock is down 5.46% at $64.68 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/financing/25/06/46053298/supermicro-wants-to-raise-2-billion-via-convertible-debt-stock-falls-on-dilution-concerns" target="_blank" rel="noreferrer noopener">Supermicro Wants To Raise $2 Billion Via Convertible Debt, Stock Falls On Dilution Concerns</a></li>
</ul>
Photo: Shutterstock

Reiteration

Trading Ideas

CarMax Beat Expectations, But Here's What Could Still Hold It Back

<h3>Gainers</h3>
<ul>
<li>Epsium Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPSM#NASDAQ">EPSM</a>) stock moved upwards by 21.1% to $27.65 during Monday's regular session. The market value of their outstanding shares is at $306.9 million. </li>
<li>Super Hi International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDL#NASDAQ">HDL</a>) shares rose 15.5% to $21.6. The market value of their outstanding shares is at $1.1 billion. </li>
<li>Hour Loop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOUR#NASDAQ">HOUR</a>) stock rose 10.61% to $1.46. The market value of their outstanding shares is at $46.4 million. </li>
<li>Massimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMO#NASDAQ">MAMO</a>) stock rose 10.48% to $2.18. The market value of their outstanding shares is at $81.8 million. </li>
<li>Perfect Moment (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#AMEX">PMNT</a>) stock increased by 9.73% to $0.45. </li>
<li>Park Ha Biological Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHH#NASDAQ">PHH</a>) shares rose 9.59% to $29.12. The company's market cap stands at $700.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) shares declined by 28.4% to $0.71 during Monday's regular session. The company's market cap stands at $13.6 million. </li>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) stock declined by 21.42% to $1.05. The company's market cap stands at $1.0 million. </li>
<li>JX Luxventure Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JXG#NASDAQ">JXG</a>) shares fell 16.95% to $2.01. The market value of their outstanding shares is at $9.7 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) stock decreased by 16.15% to $2.67. The market value of their outstanding shares is at $25.7 million. </li>
<li>Classover Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDZ#NASDAQ">KIDZ</a>) shares decreased by 14.43% to $3.17. The company's market cap stands at $88.2 million. </li>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) stock fell 13.77% to $9.52. The company's market cap stands at $190.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

EPSM

HOUR

KIDZ

MAMO

MULN

NAAS

PMNT

QVCGA

12 Consumer Discretionary Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock moved upwards by 339.0% to $1.59 during Monday's regular session. The company's market cap stands at $4.3 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) stock rose 100.14% to $42.07. The market value of their outstanding shares is at $272.6 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares moved upwards by 85.17% to $0.5. The company's market cap stands at $4.3 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock rose 42.23% to $20.52. The company's market cap stands at $375.3 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock increased by 31.24% to $2.83. The company's market cap stands at $66.9 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) shares increased by 31.08% to $0.32. The company's market cap stands at $30.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) shares decreased by 46.8% to $2.46 during Monday's regular session. The market value of their outstanding shares is at $433.1 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares decreased by 33.13% to $42.95. The market value of their outstanding shares is at $14.3 billion. </li>
<li>Quantum BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) shares decreased by 32.99% to $23.45. The company's market cap stands at $101.7 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock declined by 29.86% to $2.48. The company's market cap stands at $10.9 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares decreased by 29.68% to $26.73. The company's market cap stands at $494.6 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock fell 27.35% to $0.41. The company's market cap stands at $2.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CDTX

CMPS

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INDP

LIMN

LUCY

QNTM

SKYE

WINT

12 Health Care Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>OceanPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) stock rose 50.9% to $2.17 during Monday's regular session. The market value of their outstanding shares is at $10.8 million. </li>
<li>Zeo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) stock moved upwards by 29.64% to $3.63. The company's market cap stands at $63.9 million. </li>
<li>Concorde Intl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIGL#NASDAQ">CIGL</a>) shares increased by 28.07% to $8.44. The company's market cap stands at $147.1 million. </li>
<li>Energy Focus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFOI#NASDAQ">EFOI</a>) shares increased by 26.5% to $2.1. The market value of their outstanding shares is at $8.9 million. </li>
<li>AIRO Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRO#NASDAQ">AIRO</a>) stock rose 16.19% to $25.84. The market value of their outstanding shares is at $553.8 million. </li>
<li>Robin Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) stock rose 16.17% to $7.11. The market value of their outstanding shares is at $14.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) shares declined by 25.4% to $0.19 during Monday's regular session. The company's market cap stands at $2.3 million. </li>
<li>Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) stock fell 22.17% to $0.31. The company's market cap stands at $11.6 million. </li>
<li>Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) stock decreased by 21.1% to $3.94. The company's market cap stands at $53.0 million. </li>
<li>KWESST Micro Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) stock decreased by 15.03% to $10.41. The market value of their outstanding shares is at $6.4 million. </li>
<li>FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) shares declined by 14.32% to $0.63. The market value of their outstanding shares is at $7.0 million. </li>
<li>Bitcoin Depot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTM#NASDAQ">BTM</a>) shares declined by 13.94% to $5.19. The market value of their outstanding shares is at $139.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRO

CIGL

DFLI

EFOI

NEPH

RBNE

RYDE

12 Industrials Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Interlink Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINK#NASDAQ">LINK</a>) stock moved upwards by 25.6% to $5.64 during Monday's regular session. The market value of their outstanding shares is at $44.2 million. </li>
<li>Alpha Modus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMOD#NASDAQ">AMOD</a>) shares moved upwards by 16.34% to $1.21. The company's market cap stands at $14.3 million. </li>
<li>Intchains Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NASDAQ">ICG</a>) stock rose 15.96% to $1.38. The market value of their outstanding shares is at $71.8 million. </li>
<li>Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) stock rose 14.38% to $16.22. The market value of their outstanding shares is at $3.3 billion. </li>
<li>RF Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RFIL#NASDAQ">RFIL</a>) stock moved upwards by 13.47% to $5.51. The market value of their outstanding shares is at $51.8 million. </li>
<li>Comtech Telecom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) shares moved upwards by 10.98% to $2.48. The company's market cap stands at $65.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Wolfspeed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) stock fell 32.4% to $0.61 during Monday's regular session. The company's market cap stands at $140.0 million. </li>
<li>Next Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) stock fell 30.82% to $2.38. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Gorilla Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) stock decreased by 20.93% to $19.95. The company's market cap stands at $465.8 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Sequans Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) stock decreased by 18.14% to $1.58. The company's market cap stands at $119.5 million. </li>
<li>Digi Power X (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGXX#NASDAQ">DGXX</a>) shares declined by 15.72% to $2.36. The company's market cap stands at $101.6 million. </li>
<li>Creative Global Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTL#NASDAQ">CGTL</a>) shares declined by 15.18% to $1.23. The market value of their outstanding shares is at $31.0 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMOD

CGTL

CMTL

DGXX

GRRR

LINK

Next Technology Holding Inc. - Ordinary Shares

NXTT

RFIL

SQNS

WOLF

ZETA

12 Information Technology Stocks Moving In Monday's Intraday Session

Investors with a lot of money to spend have taken a bullish stance on Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with RIOT, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Riot Platforms.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 44%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $480,692, and 3 are calls, for a total amount of $111,506.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $7.0 to $12.0 for Riot Platforms over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Riot Platforms options trades today is 2430.57 with a total volume of 8,321.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Riot Platforms's big money trades within a strike price range of $7.0 to $12.0 over the last 30 days.
<h3>Riot Platforms Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750698356_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIOT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/26</td>
<td>$4.3</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$12.00</td>
<td>$127.0K</td>
<td>22</td>
<td>300</td>
</tr>
<tr>
<td>RIOT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$3.05</td>
<td>$3.0</td>
<td>$3.01</td>
<td>$12.00</td>
<td>$111.6K</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>RIOT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$3.1</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$11.00</td>
<td>$91.2K</td>
<td>168</td>
<td>300</td>
</tr>
<tr>
<td>RIOT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$1.34</td>
<td>$1.33</td>
<td>$1.33</td>
<td>$7.00</td>
<td>$66.5K</td>
<td>2.6K</td>
<td>500</td>
</tr>
<tr>
<td>RIOT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/25/25</td>
<td>$0.22</td>
<td>$0.18</td>
<td>$0.18</td>
<td>$11.50</td>
<td>$55.4K</td>
<td>214</td>
<td>5.0K</td>
</tr>
</tbody>
</table>

<h3>About Riot Platforms</h3>
Riot Platforms Inc is a vertically integrated Bitcoin mining company focused on building, supporting, and operating blockchain technologies. The company's segments include Bitcoin Mining and Engineering. The Bitcoin Mining segment generates revenue from the Bitcoin the Company earns through its Bitcoin Mining activities. The Engineering segment generates revenue through customer contracts for custom engineered electrical products. It generates the majority of its revenue from the Bitcoin Mining segment.
After a thorough review of the options trading surrounding Riot Platforms, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Riot Platforms</h3>
<ul>
<li>With a volume of 22,285,437, the price of RIOT is down -6.33% at $8.96. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 37 days.</li>
</ul>
<h3>Professional Analyst Ratings for Riot Platforms</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $14.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Riot Platforms, targeting a price of $14. 
&#x2A; An analyst from Needham has decided to maintain their Buy rating on Riot Platforms, which currently sits at a price target of $15. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Riot Platforms options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

RIOT

Riot Platforms Unusual Options Activity For June 23

Deep-pocketed investors have adopted a bearish approach towards Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ORCL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 48 extraordinary options activities for Oracle. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 50% bearish. Among these notable options, 10 are puts, totaling $778,670, and 38 are calls, amounting to $6,689,721.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $260.0 for Oracle over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Oracle's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Oracle's substantial trades, within a strike price spectrum from $85.0 to $260.0 over the preceding 30 days.
<h3>Oracle Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750698351_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$26.9</td>
<td>$26.6</td>
<td>$26.6</td>
<td>$200.00</td>
<td>$904.4K</td>
<td>8.4K</td>
<td>1.3K</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$31.35</td>
<td>$30.15</td>
<td>$30.1</td>
<td>$200.00</td>
<td>$903.1K</td>
<td>2.0K</td>
<td>914</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$27.45</td>
<td>$26.7</td>
<td>$26.82</td>
<td>$200.00</td>
<td>$804.6K</td>
<td>8.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$31.0</td>
<td>$30.35</td>
<td>$30.35</td>
<td>$200.00</td>
<td>$743.5K</td>
<td>2.0K</td>
<td>1.1K</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$26.65</td>
<td>$26.1</td>
<td>$26.1</td>
<td>$200.00</td>
<td>$522.0K</td>
<td>8.4K</td>
<td>1.6K</td>
</tr>
</tbody>
</table>

<h3>About Oracle</h3>
Oracle provides enterprise applications and infrastructure offerings around the world through a variety of flexible IT deployment models, including on-premises, cloud-based, and hybrid. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system, which is commonly used for running online transaction processing and data warehousing workloads. Besides database systems, Oracle also sells enterprise resource planning, or ERP, customer relationship management, or CRM, and human capital management, or HCM, applications. Today, Oracle has more than 159,000 full-time employees in over 170 countries.
<h3>Present Market Standing of Oracle</h3>
<ul>
<li>With a trading volume of 7,052,519, the price of ORCL is down by -0.55%, reaching $204.04.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 77 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Oracle</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $179.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Piper Sandler persists with their Neutral rating on Oracle, maintaining a target price of $190. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Oracle, targeting a price of $186. 
&#x2A; An analyst from Evercore ISI Group has decided to maintain their Outperform rating on Oracle, which currently sits at a price target of $215. 
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on Oracle, maintaining a target price of $175. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Neutral rating on Oracle with a target price of $130. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Oracle, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

ORCL

Decoding Oracle's Options Activity: What's the Big Picture?

Whales with a lot of money to spend have taken a noticeably bearish stance on Lennar.
Looking at options history for Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 18% of the investors opened trades with bullish expectations and 81% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $545,925 and 2, calls, for a total amount of $182,200.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $95.0 to $120.0 for Lennar during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Lennar stands at 305.5, with a total volume reaching 2,161.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Lennar, situated within the strike price corridor from $95.0 to $120.0, throughout the last 30 days.
<h3>Lennar Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750698346_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LEN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/27/25</td>
<td>$14.0</td>
<td>$12.7</td>
<td>$13.0</td>
<td>$95.00</td>
<td>$156.0K</td>
<td align="right">202</td>
<td align="right">200</td>
</tr>
<tr>
<td>LEN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$14.9</td>
<td>$14.6</td>
<td>$14.6</td>
<td>$120.00</td>
<td>$99.2K</td>
<td align="right">214</td>
<td align="right">265</td>
</tr>
<tr>
<td>LEN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$14.9</td>
<td>$14.6</td>
<td>$14.86</td>
<td>$120.00</td>
<td>$98.1K</td>
<td align="right">214</td>
<td align="right">331</td>
</tr>
<tr>
<td>LEN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.9</td>
<td>$11.6</td>
<td>$11.9</td>
<td>$115.00</td>
<td>$65.4K</td>
<td align="right">210</td>
<td align="right">165</td>
</tr>
<tr>
<td>LEN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.9</td>
<td>$11.5</td>
<td>$11.78</td>
<td>$115.00</td>
<td>$65.2K</td>
<td align="right">210</td>
<td align="right">55</td>
</tr>
</tbody>
</table>

<h3>About Lennar</h3>
Lennar is one of the largest public homebuilders in the United States. The company's homebuilding operations target first-time, move-up, active adult, and luxury homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily and single-family for-rent construction and has invested in numerous housing-related technology startups.
<h3>Present Market Standing of Lennar</h3>
<ul>
<li>With a trading volume of 1,191,526, the price of LEN is up by 1.8%, reaching $108.34.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 87 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Lennar</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $108.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Neutral rating on Lennar with a target price of $105. 
&#x2A; An analyst from Evercore ISI Group persists with their In-Line rating on Lennar, maintaining a target price of $114. 
&#x2A; In a cautious move, an analyst from Wedbush downgraded its rating to Neutral, setting a price target of $130. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Lennar, maintaining a target price of $95. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Sector Perform rating for Lennar, targeting a price of $98. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Lennar with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

A Closer Look at Lennar's Options Market Dynamics

I'm usually a long-term investor. It fits my nature, inclination, and personality. The short-term trades I engage in from time to time are typically arbitrage-related. That does not mean that I don't know anything about trading.
Many years ago, I conversed with one of the greatest traders of the last 100 years. He said that when studying markets, if something can be tested, it must be tested. Since then, I have tested thousands of different ideas, thoughts, concepts, and what I thought initially were grand epiphanies, including dozens of technical indicators.
I have read thousands more tests and studies by traders, professors, and students of the markets. I have had countless conversations with value investors, arbitrage traders, floor traders, quantitative traders, private equity corporate raider types, fundamentalists, technicians, spread traders, scalpers, and everyone in between.
After talking, reading, and number crunching, I can tell you that the secret to trading success is not what you think it is. It is not a magic pattern. It is not the top-secret options strategy of the 1%. It is not the perfect algorithm. It is absolutely not a high win rate. In fact, a high win rate with small average gains is more likely to lead to a job waiting tables at Applebee&#8217;s than it is to being featured on Lifestyles of the Rich and Lucky.
<h2 class="wp-block-heading">How Matt Maley Is Trading The Market's Shifting Forces—Live Wednesday At 6 PM ET</h2>
Geopolitical tensions, energy disruptions, and inflation are creating new market dynamics. Join Matt Maley this Wednesday at 6 PM ET to learn how he's positioning for these forces as we head into July. Matt will share how he's trading the current volatility, which sectors he's focused on, and the real trade setups he's targeting to capitalize on this evolving macro environment. Reserve <a href="https://events2.benzinga.com/matt-maley-webinar-wed-june25-2025-registration/?utm_campaign=webinar062525&amp;utm_adType=sponsorad&amp;utm_ad=RD062425">your spot now</a>—this is your chance to trade with a Wall Street veteran.
<h2 class="wp-block-heading">Right-Sizing Your Bets And Learning To Take Small Losses</h2>
Everett Klipp was one of the best traders in the history of the Chicago Board of Trade (CBOT). He was often called the Babe Ruth of the CBOT. During his career, he mentored Richard Dennis, William Eckhardt, Mark Spitznagle, and hundreds of CBOT traders. He was emphatic about taking small losses and avoiding the big losses that could wipe out an account or end a career.
Paul Tudor Jones has had spectacular success during his career and has repeatedly said that the key to making big money is not playing offense but playing defense and taking small losses. The wins will take care of themselves if you put defense first.
Charles P. DiFrancesca trained hundreds of successful floor traders at the CBOT. He taught that trading was not about predicting the future. It was about managing the present, cutting losers early, and letting winners run. He believed the only real mistake a trader could make was allowing a small loss to turn into a big one.
Charlie D. died too young, but not only did he get rich, he helped a lot of young traders survive and thrive during his career. If you have never read &#8220;Charlie D., The Story of the Legendary Bond Trader&#8221; by William Falloon, order it now from Amazon. You will thank me.
If someone claimed that Ed Seykota was the best trader ever, I would find it difficult to argue with them. He made a fortune, and his entire system was built around cutting losses short and letting winners run.
That sounds trite, but it&#8217;s a lot like &#8220;Buy Low, Sell High.&#8221; Really easy to say but very difficult to practice.
Ed is interviewed in the original Trading Wizards by Jack Schwager, as are Paul Tudor Jones and other wildly successful traders. You can get it on Amazon and I would be shocked if your local library did not have a copy.
Stanley Druckenmiller has made billions in the financial markets. He is one of the true greats of trading. He is best known for some of his legendary trades, but he repeatedly emphasized taking losses quickly when a position goes against you.
He did not earn 30% a year for 30 years with no down years because he spent a lot of time hoping a trade would return to its starting point.
William O&#8217;Neill&#8217;s CANSLIM program worked as well as it did because he never let a stock plunge precipitously and wipe out his account. He used 7% stops on every trade.
While that did not transition well to mutual fund management, O&#8217;Neill and CANSLIM made a lot of money for a lot of individual investors. He made billions by hanging on when he was right, allowing powerful fundamentals to send the stock soaring, and getting out quickly when he was wrong.
As individual traders and investors, we do not have the luxury of research staff and trading desks. We do have the luxury of being independent, though, and not having to answer to anyone.
It is not that difficult to set up a system. It does not matter if you want to use trend-based entry points or reversion-based entry.
It matters that you have an approach that is the right mix of probability and payoff and that has rules you can follow.
It matters that you understand the system.
We cannot all be Jim Simons and would go broke if we tried to be.
I am pretty sure you can make money using something as simple as a combination of Williams %R or RSI along with a short-term moving average, unless you hoped and dreamed too much about positions recovering losses and hung on long after you should have closed the trade.
If you want to be profitable as a trader, learn to take small losses quickly and painlessly. If you do not, you will certainly take a large one at some point that puts you out of the game.
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

The Greatest Traders All Follow This One Simple Rule

Bank of America Securities (BofA) analyst Brad Sills <a target="_blank" href="https://www.benzinga.com/quote/HUBS/analyst-ratings" rel="noreferrer noopener">maintained a Buy</a> rating on HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a price forecast of $740 on Monday.
Sills took a deep dive into the key components of HubSpot&#8217;s emerging Breeze AI platform.
The analyst doesn&#8217;t expect material revenue from Breeze until fiscal 2027, but he notes it&#8217;s a useful exercise to take a bottoms-up approach to model incremental revenue from Breeze.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45755544/rising-ai-analytics-budgets-could-lift-microsoft-snowflake-datadog" rel="noreferrer noopener">Rising AI, Analytics Budgets Could Lift Microsoft, Snowflake, Datadog</a>
Sills asserted that the point of the modeling exercise is not to predict the timing of revenue but to illustrate Breeze AI can move the needle on growth without heroic assumptions, given the value of the offerings and scale of HubSpot&#8217;s installed base.
Like Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>), the analyst noted that the use case for AI is most compelling in HubSpot&#8217;s sales and marketing categories, given the promise of sales productivity and potential revenue uplift.
However, he noted that in HubSpot&#8217;s small to medium-sized business (SMB) end market, third-party agentic tools like ChatGPT could substitute for agents.
Channel feedback suggested HubSpot customers do not have the same restriction on third-party tools that enterprises do and are running these tools for basic generative use cases such as marketing content, Sills noted.
Sills added that this means Breeze agents need to solve more sophisticated workflows to drive adoption.
He said HubSpot has&nbsp;a robust set of agents, including customer agents, content agents, social media agents, prospecting agents, and knowledge base agents.
Sills noted that these agents can drive meaningful workflow automation over time because they run on a proprietary and robust data set.
HubSpot manages over 200 million company and buyer profiles, the analyst noted. Also, with the acquisition of Frame AI, he said Breeze can ingest vast amounts of unstructured data.
On May 8, the company expanded the use of HubSpot credits to Customer Agent across Marketing, Sales, Service, and all other core hubs, Sills noted.
Pro and Enterprise customers will have a baseline credit package per month and can purchase more credits at $10/1000 credits, the analyst said.
In a Customer Agent base case, assuming 2.5% and 3% agent penetration and 10% and 13% resolution rate, Sills arrived at $30 million and $ 84 million of revenue contribution in fiscal 2026 and 2027, representing 1% and 2% points of growth, respectively.
Sills projected fiscal 2025 sales of $3.04 billion and EPS of $9.33.
Price Action: HUBS stock is up 1.08% at $540.26 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/25/04/44672420/pros-global-e-sps-commerce-stand-out-as-tariffs-reshape-software-spending-priorities-analyst" target="_blank" rel="noreferrer noopener">PROS, Global-E, SPS Commerce Stand Out As Tariffs Reshape Software Spending Priorities: Analyst</a></li>
</ul>
Image via Shutterstock

HUBS

HubSpot's Breeze AI Platform Could Add Millions In Revenue By 2027: Analyst

CRWD

FTNT

LDOS

CNBC Halftime Report Final Trades: Global X Cybersecurity ETF, CrowdStrike, Leidos Holdings, Fortinet

Press Releases

Jerash Holdings to Report Financial Results for Fiscal 2025 Second Quarter on Tuesday, November 12, 2024

Dividends

Jerash Holdings (US), Inc. Declares Quarterly Dividend

Earnings

Jerash Holdings Reports Financial Results for Fiscal 2025 Second Quarter

Jerash Holdings to Report Financial Results for Fiscal 2025 Third Quarter on Tuesday, February 11, 2025

Jerash Holdings Reports Fiscal 2025 Third Quarter Financial Results

Jerash Holdings to Report Financial Results for Fiscal 2025 Fourth Quarter and Full Year on Monday, June 23, 2025

Contracts

Jerash Holdings Secures Major Initial Order for Large Multinational Retail Corporation Through New Strategic Collaboration  with South Korean Apparel Group, Hansoll Textile

Jerash Holdings Reports Financial Results for Fiscal 2025 Fourth Quarter and Full Year

Comments

Jerash Holdings (US)

매도 수량

Jerash Holdings (US) (NASDAQ:JRSH) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌